Equillium
About: Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Employees: 35
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 27 [Q3] → 27 (+0) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.04% less ownership
Funds ownership: 24.61% [Q3] → 24.57% (-0.04%) [Q4]
10% less capital invested
Capital invested by funds: $7.25M [Q3] → $6.52M (-$732K) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1
120%
upside
Avg. target
$1
120%
upside
High target
$1
120%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Leerink Partners Thomas Smith 0% 1-year accuracy 0 / 4 met price target | 120%upside $1 | Market Perform Downgraded | 28 Mar 2025 |
Financial journalist opinion
Based on 4 articles about EQ published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Negative
Benzinga
3 weeks ago
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD).
Neutral
Business Wire
3 weeks ago
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overal.
Neutral
Business Wire
3 weeks ago
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights. “This morning, following considerable efforts by our clinical team, we announced topline data from the Phase 3 EQUATOR study evaluating it.
Positive
Zacks Investment Research
1 month ago
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Positive
Zacks Investment Research
2 months ago
Equillium (EQ) Upgraded to Buy: Here's What You Should Know
Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
2 months ago
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock
Equillium (EQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Neutral
Business Wire
2 months ago
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced positive topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC). The dou.
Neutral
Business Wire
5 months ago
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates. “At the end of October we announced that our partnership with Ono Pharmaceutical had ended following substantial non-dilutive financing that has fully fund.
Neutral
Business Wire
5 months ago
Equillium to Present at the Stifel Healthcare Conference
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Stifel Healthcare Conference taking place in New York on November 18 & 19, 2024. Management will provide an overview of the Company's clinical programs, currently focused on the Phase 3 EQUATOR study of itolizumab.
Charts implemented using Lightweight Charts™